RNU6-389P

Across TCGA pan-cancer cohorts, RNU6-389P Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RNU6-389P data layer compared with 14 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNU6-389P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-389P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LGG, and ESCA are the cancer types where RNU6-389P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.167	0.668	<.001	21	view →
LGG	OS	Median	All	0.173	0.830	<.001	12	view →
ESCA	DFS	Median	All	0.052	0.533	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.915	0.305	.020	8	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RNU6-389P–LUAD (OS)

Open the LUAD breakdown →